TrialJournal for immunotherapy of cancer2022

Nivolumab plus rucaparib for metastatic castration-resistant prostate cancer: results from the phase 2 CheckMate 9KD trial.

Karim Fizazi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.